Metastatic Olfactory Neuroblastoma Clinical Trial
Official title:
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
To learn if rivoceranib can help to control olfactory neuroblastoma. The safety of this drug in participants with olfactory neuroblastoma will also be studied.
Primary Objective: - To assess the efficacy of rivoceranib in patients with R/M ONB Secondary Objective: - To estimate the median duration of response (DOR) - Time to response - To estimate the median progression-free survival (PFS) - To estimate the median overall survival (OS) - To assess safety of rivoceranib Tertiary Objective: - To explore biomarkers that may predict response to therapy ;